Osteoporosis is particularly common in smokers, postmenopausal women, the elderly, underweight or immobile, and patients with diabetes or lung problems. Osteoporosis may result in fractures of the spine, ribs or hip joint with minimal trauma. These occur after the first year in 10–20% of patients treated with more than mg prednisone daily. It is estimated that up to 50% of patients on long-term prednisone will develop bone fractures. Vertebral fractures are more common in patients on steroids, even in those with normal bone density.
At week 24, participants treated with dupilumab had reduced their corticosteroid dose by % vs % in placebo, with 80% achieving a ≥50% reduction in corticosteroid dose vs 50% of placebo (odds ratio, ), and 48% no longer needing corticosteroids vs 25% of placebo. Dupilumab improved FEV 1 by L and reduced severe exacerbations by % ( [placebo] vs [dupilumab]). The most common adverse events in the dupilumab-treated group were bronchitis (% vs % placebo), eosinophilia (% vs % placebo), eosinophil count increase (% vs 0% placebo), and sinusitis (% vs % placebo). Rates of conjunctivitis were similar between both groups (% vs %).